Cidofovir Dihydrate

Names

[ Name ]:
Cidofovir Dihydrate

[Synonym ]:
Cidofovir hydrate (1:2)
Gs-0504
Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-
Cidofovir dihydrate
({[(2S)-1-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
Cidofovir
(S)-[[2-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic Acid
Unii-jil713Q00n
(S)-HPMPC Hydrate
Cidovir Hydrate
Vistide Hydrate
(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid
({[(2S)-1-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-3-hydroxy-2-propanyl]oxy}methyl)phosphonic acid
Vistide
Drg-0145
Cidofovir hydrate
GS 0504 Hydrate
Cidofovir (dihydrate)

Biological Activity

[Description]:

Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.Target: CMV DNA polymeraseCidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir.Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Hol?, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions.

[Related Catalog]:

Signaling Pathways >> Anti-infection >> CMV

Research Areas >> Infection

[References]

[1]. Becker MN, et al. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol J. 2008 May 14;5:58.

[2]. Kazory A, et al. Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir. J Antimicrob Chemother. 2007 Jul;60(1):193-4. Epub 2007 May 11.

[3]. Segarra-Newnham M, et al. Use of cidofovir in progressive multifocal leukoencephalopathy. Ann Pharmacother. 2001 Jun;35(6):741-4.

[Related Small Molecules]

Letermovir | Maribavir | Brivudine | B220 | Tomeglovir

Chemical & Physical Properties

[ Density]:
1.8±0.1 g/cm3

[ Boiling Point ]:
609.5±65.0 °C at 760 mmHg

[ Melting Point ]:
260ºC (dec)

[ Molecular Formula ]:
C₈H₁₈N₃O₈P

[ Molecular Weight ]:
315.22

[ Flash Point ]:
322.4±34.3 °C

[ PSA ]:
157.71000

[ LogP ]:
-3.37

[ Vapour Pressure ]:
0.0±4.0 mmHg at 25°C

[ Index of Refraction ]:
1.656

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.